Lisdexamfetamine (L-lysine-d-amphetamine), marketed under the name Vyvanse, is a prodrug indicated for treatment of attention-deficit hyperactivity disorder. It was developed by Shire and New River Pharmaceuticals and received approval from the U.S. Food and Drug Administration on February 23, 2007. Lisdexamfetamine is intended to provide an option of lower abuse potential, and the results of clinical trials seem to indicate that it is successful. 50mg of lisdexamfetamine contains 20mg of the stimulant d-amphetamine, the well-known abusable Schedule II option; because of its being bound to L-Lysine, this amphetamine is released and activated more slowly as the molecule is hydrolyzed in the digestive system. This delayed release produced less "likeability", less euphoric effect and a later peak time than amphetamine alone in clinical trials, suggesting that lisdexamfetamine may be appropriate for use with patients with history of stimulant abuse. Nevertheless, it is currently up for designation as Schedule II as well.